TRILYTE WITH FLAVOR PACKS- polyethylene glyocol 3350, sodium chloride, sodium bicarbonate and potassium chloride powder, for solution
Wallace Pharmaceuticals Inc.
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use TRILYTE safely and effectively. See full prescribing information for TRILYTE.
TRILYTE (polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution) with flavor packs
Initial U.S. Approval: 1991
INDICATIONS AND USAGE
TRILYTE is a combination of PEG 3350, an osmotic laxative, and electrolytes indicated for cleansing of the colon in preparation for colonoscopy in adults and pediatric patients aged 6 months or greater (1)
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
For oral solution: polyethylene glycol 3350 420 grams, sodium bicarbonate 5.72 grams, sodium chloride 11.2 grams, potassium chloride 1.48 grams, and flavoring ingredients 3.22 grams; supplied in one 4 liter disposable jug (3)
WARNINGS AND PRECAUTIONS
See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.
FULL PRESCRIBING INFORMATION: CONTENTS*
TRILYTE is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater.
TRILYTE, supplied as a powder, must be reconstituted with water before its use; it is not for direct ingestion [see Dosage and Administration (2.2), Warnings and Precautions (5.8)]. The 4 liter reconstituted TRILYTE solution contains: 420 grams of polyethylene glycol (PEG) 3350, 5.72 grams of sodium bicarbonate, 11.2 grams of sodium chloride, and 1.4 grams of potassium chloride. TRILYTE may be used with or without one of the supplied flavor packs.
On the day prior to the colonoscopy, instruct patients to:
The following is the recommended dose of reconstituted TRILYTE solution for adults and pediatric patients ≥ 6 months. Instruct patients they may consume water or clear liquids during the bowel preparation and after completion of the bowel preparation up until 2 hours before the time of the colonoscopy. The solution is more palatable if chilled prior to administration.
The first bowel movements should occur approximately one hour after the start of TRILYTE administration. Continue drinking until the watery stool is clear and free of solid matter.
For oral solution: One 4 liter jug with powder for reconstitution with water.
Each 4 liter jug contains: polyethylene glycol 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, potassium chloride 1.48 g and flavoring ingredients 3.22 g. When made up to 4 liters volume with water, the solution contains PEG 3350 31.3 mmol/L, sodium 65 mmol/L, chloride 53 mmol/L, bicarbonate 17 mmol/L and potassium 5 mmol/L.
TRILYTE is contraindicated in the following conditions:
Advise patients to hydrate adequately before, during, and after the use of TRILYTE. Use caution in patients with congestive heart failure when replacing fluids. If a patient develops significant vomiting or signs of dehydration including signs of orthostatic hypotension after taking TRILYTE, consider performing post-colonoscopy lab tests (electrolytes, creatinine, and BUN) and treat accordingly. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures and renal impairment. Fluid and electrolyte abnormalities should be corrected before treatment with TRILYTE.
In addition, use caution when prescribing TRILYTE for patients who have conditions, or who are using medications, that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and renal impairment [see Drug Interactions (7.1)].
There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation. Use caution when prescribing TRILYTE for patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy). Pre-dose and post-colonoscopy ECGs should be considered in patients at increased risk of serious cardiac arrhythmias.
There have been reports of generalized tonic-clonic seizures and/or loss of consciousness associated with use of bowel preparation products in patients with no prior history of seizures. The seizure cases were associated with electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia) and low serum osmolality. The neurologic abnormalities resolved with correction of fluid and electrolyte abnormalities.
Use caution when prescribing TRILYTE for patients with a history of seizures and in patients at increased risk of seizure, such as patients taking medications that lower the seizure threshold (e.g., tricyclic antidepressants), patients withdrawing from alcohol or benzodiazepines, or patients with known or suspected hyponatremia.
Use caution when prescribing TRILYTE for patients with impaired renal function or patients taking concomitant medications that may affect renal function (such as diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or non-steroidal anti-inflammatory drugs). Advise these patients of the importance of adequate hydration, and consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients.
Administration of osmotic laxative products may produce colonic mucosal aphthous ulcerations, and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of stimulant laxatives and TRILYTE may increase this risk. The potential for mucosal ulcerations resulting from the bowel preparation should be considered when interpreting colonoscopy findings in patients with known or suspect inflammatory bowel disease (IBD).
If gastrointestinal obstruction or perforation is suspected, perform appropriate diagnostic studies to rule out these conditions before administering TRILYTE. If a patient experiences severe bloating, distention or abdominal pain, administration should be slowed or temporarily discontinued until the symptoms abate. If gastrointestinal obstruction or perforation is suspected, appropriate studies should be performed to rule out these conditions before administration of TRILYTE.
Use with caution in patients with severe active ulcerative colitis.
Use with caution in patients with impaired gag reflex, unconscious, or semiconscious patients, and patients prone to regurgitation or aspiration. Such patients should be observed during administration of TRILYTE, especially if it administered via nasogastric tube.
The contents of each jug must be diluted with water to a final volume of 4 liters (4 L) and ingestion of additional water is important to patient tolerance. Direct ingestion of the undissolved powder may increase the risk of nausea, vomiting, dehydration, and electrolyte disturbances.
The following adverse reactions have been identified during post-approval use of TRILYTE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Nausea, abdominal fullness and bloating are the most common adverse reactions (occurred in up to 50% of patients) to administration of TRILYTE. Abdominal cramps, vomiting and anal irritation occur less frequently. These adverse reactions are transient and usually subside rapidly. Isolated cases of urticaria, rhinorrhea, dermatitis and (rarely) anaphylactic reaction have been reported which may represent allergic reactions.
Published literature contains isolated reports of serious adverse reactions following the administration of PEG-electrolyte solution products in patients over 60 years of age. These adverse events include upper GI bleeding from Mallory-Weiss Tear, esophageal perforation, asystole, sudden dyspnea with pulmonary edema, and “butterfly-like” infiltrates on chest X-ray after vomiting and aspirating PEG.
Use caution when prescribing TRILYTE for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. Consider additional patient evaluations as appropriate [see Warnings and Precautions (5.1, 5.2, 5.3, and 5.4)] in patients taking these concomitant medications.
Oral medication administered within one hour of the start of administration of TRILYTE may be flushed from the gastrointestinal tract and the medication may not be absorbed properly.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TRILYTE is administered to a nursing woman.
Safety and effectiveness of TRILYTE in pediatric patients aged 6 months and older is supported by evidence from adequate and well-controlled clinical trials of TRILYTE in adults with additional safety and efficacy data from published studies of similar formulations.
Use of TRILYTE in children younger than 2 years of age should be carefully monitored for occurrence of possible hypoglycemia, as this solution has no caloric substrate. Dehydration has been reported in one child and hypokalemia has been reported in 3 children.
For oral solution: Each 4 liter (4 L) TRILYTE jug contains a white to off white powder for reconstitution. TRILYTE is a combination of polyethylene glycol 3350, an osmotic laxative, and electrolytes (sodium chloride, sodium bicarbonate and potassium chloride) for oral solution.
Each 4 liter jug contains: polyethylene glycol 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, potassium chloride 1.48 g. The solution is clear and colorless when reconstituted to a final volume of 4 liters with water.
Polyethylene Glycol 3350, USP
Sodium Bicarbonate, USP
The chemical name is NaHCO3. The average Molecular Weight is 84.01. The structural formula is:
Sodium Chloride, USP
The chemical name is NaCl. The average Molecular Weight: 58.44. The structural formula is:
Potassium Chloride, USP
The chemical name is KCl. The average Molecular Weight: 74.55. The structural formula is:
The primary mode of action is thought to be through the osmotic effect of polyethylene glycol 3350 which causes water to be retained in the colon and produces a watery stool.
TRILYTE induces as diarrhea which rapidly cleanses the bowel, usually within four hours.
In powdered form, for oral administration as a solution following reconstitution.
TRILYTE with flavor packs (PEG 3500, sodium chloride, sodium bicarbonate and potassium chloride for oral solution) is supplied in a 4 liter bottle with an attached package containing flavor packs. This preparation is supplied in powdered form (white to off-white powder) for oral administration as a solution following reconstitution. Each 4 liter bottle contains polyethylene glycol 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, potassium chloride 1.48 g. Each flavor pack contains 3.22 g of flavoring ingredients. When made up to 4 liters volume with water, the solution contains PEG 3350 31.3 mmol/L, sodium 65 mmol/L, chloride 53 mmol/L, bicarbonate 17 mmol/L and potassium 5 mmol/L.
TRILYTE with flavor packs 4 liter NDC 51525-6831-4
Storage: Store in sealed container at 25ºC (77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF). [See USP Controlled Room Temperature.] When reconstituted, keep solution refrigerated. Use within 48 hours. Discard unused portion.
Keep out of reach of children.
See FDA-Approved Patient Labeling (Medication Guide). Instruct patients:
IN-6831-03 Rev 5/2017 CIA71673D
(PEG 3350, sodium chloride, sodium bicarbonate and potassium chloride oral solution)
Read this Medication Guide before you start taking TRILYTE. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.
What is the most important information I should know about TRILYTE?
TRILYTE and other osmotic bowel preparations can cause serious side effects, including:
Serious loss of body fluid (dehydration) and changes in blood salts (electrolytes) in your blood.
These changes can cause:
Your chance of having fluid loss and changes in body salts with TRILYTE is higher if you:
Tell your healthcare provider right away if you have any of these symptoms of a loss of too much body fluid (dehydration) while taking TRILYTE:
See Section “What are the possible side effects of TRILYTE” for more information about side effects.
What is TRILYTE?
TRILYTE is a prescription medicine used by adults to clean the colon before a colonoscopy. TRILYTE cleans your colon by causing you to have diarrhea. Cleaning your colon helps your healthcare provider see the inside of your colon more clearly during your colonoscopy.
TRILYTE is safe and effective for use in pediatric patients aged 6 months and older.
Who should not take TRILYTE?
Do not take TRILYTE if your healthcare provider has told you that you have:
What should I tell my healthcare provider before taking TRILYTE? Before you take TRILYTE, tell your healthcare provider if you:
Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.
TRILYTE may affect how other medicines work. Medicines taken by mouth may not be absorbed properly when taken within 1 hour before the start of TRILYTE.
Especially tell your healthcare provider if you take:
Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure if you are taking any of the medicines listed above.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
How should I take TRILYTE?
You must read, understand, and follow these instructions to take TRILYTE the right way.
What are the possible side effects of TRILYTE?
TRILYTE can cause serious side effects, including:
The most common side effects of TRILYTE include:
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of TRILYTE. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store TRILYTE?
Keep TRILYTE and all medicines out of the reach of children.
General information about the safe and effective use of TRILYTE.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TRILYTE for a condition for which it was not prescribed. Do not give TRILYTE to other people, even if they are going to have the same procedure you are. It may harm them.
This Medication Guide summarizes important information about TRILYTE. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information that is written for healthcare professionals.
For more information, call Wallace Pharmaceuticals Inc. at 1-888-444-1527.
What are the ingredients in TRILYTE?
Active ingredients: polyethylene glycol 3350, sodium sulfate, sodium bicarbonate, sodium chloride, and potassium chloride.
Inactive ingredients: cherry flavoring, lemon-lime flavoring (flavor packs only)
This Medication Guide has been approved by the U.S. Food and Drug Administration.
Manufactured by: Kremers Urban Pharmaceuticals Inc., Seymour IN 47274 for Wallace Pharmaceuticals Inc. Somerset, NJ 08873-4120
For Medical Inquiries call Wallace Pharmaceuticals Inc. at 1-888-444-1527.
©2017 Wallace Pharmaceuticals Inc., a Mylan company
TRILYTE is a registered trademark of Alaven Pharmaceutical LLC, a Mylan company
WALLACE and the “W” logo are trademarks of Wallace Pharmaceuticals Inc., a Mylan company
IN-6831-03 Rev 5/2017 CIA71814A
Note to pharmacist: Dispense
bottle and all attached flavor packs to
patient. Dispense the accompanying
Medication Guide to each patient.
TriLyte® with flavor packs
(PEG 3350, sodium chloride, sodium bicarbonate
and potassium chloride for oral solution)
When reconstituted with water to a volume for 4 liters, this
solution contains PEG 3350 31.3 mmol/L, sodium 65 mmol/L,
chloride 53 mmol/L, bicarbonate 17 mmol/L and potassium
This package contains the following ingredients:
Polyethylene Glycol 3350 420 g
Sodium Bicarbonate 5.72 g
Sodium Chloride 11.2 g
Potassium Chloride 1.48 g
Store in sealed container at 25ºC (77ºF); excursions
permitted between 15º to 30ºC (59º to 86ºF). [See USP
Controlled Room Temperature.]
See base label for mixing information.
LB-683104-03 Rev. 5/2017
WITH FLAVOR PACKS
polyethylene glyocol 3350, sodium chloride, sodium bicarbonate and potassium chloride powder, for solution
|Labeler - Wallace Pharmaceuticals Inc. (962531955)|